$QCLS

Q/C Technologies (NASDAQ: QCLS) files Form 12b-25 delaying 2025 10-K

Q/C Technologies, Inc. (QCLS) has filed a Form 12b-25, indicating that it will be unable to file its Annual Report on Form 10-K for the year ended December 31, 2025, on time. The company requires additional time to complete and finalize its financial statements and anticipates filing the Form 10-K within fifteen calendar days after the prescribed due date. This routine late-filing notice was signed by Executive Chairman Joshua Silverman on March 31, 2026, and does not suggest any financial restatements.

Original reporting
Published Apr 1, 2026, 2:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 3:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$QCLS
Bearish
medium confidence
Mentioned
$QCLS
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$QCLSBearishLow
01

Why it matters

The delay in filing could temporarily depress the stock price, especially among short-term traders, but may not have long-term implications if the company resolves the issues promptly.

02

Market read

While the news is relevant for short-term traders and existing shareholders, it is unlikely to influence broader market trends.

03

What to watch

The company's overall financial health and recent performance trends should be monitored to assess if the delay is symptomatic of deeper issues.

Relevance 6/10Timing: short-term (within the next 1-2 weeks)

Background

Q/C Technologies has historically been a small-cap company with limited liquidity, making its stock more susceptible to news-driven volatility.

Company-level read

Ticker impact

$QCLSBearishMedium confidence
Context

The company's delay in filing its 10-K indicates potential operational or financial issues, which could influence investor sentiment.

Expected impact

Potential short-term decline of 5-10% due to increased uncertainty and negative sentiment.

Evidence & confidence

The delay is a routine filing extension, signed by the company's executive chairman, and does not indicate financial restatements. However, delays can create uncertainty, especially in a volatile market.

Market effects

The delay may reflect broader operational challenges within the technology or finance sectors, but specific sector impact is limited.

Minimal regional impact, as the news pertains to a U.S.-based company.

Low, as the company's delay is unlikely to influence global markets significantly.

Counterpoint

The delay might be a routine procedural matter with no material impact on the company's fundamentals.

Key entities

  • Q/C Technologies, Inc.

    A technology company listed on NASDAQ, involved in various tech solutions.

  • Joshua Silverman

    Executive Chairman of Q/C Technologies, signed the filing delay notice.

Related articles

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.

$AMZNMed

Amazon is discussing selling $8 billion worth of Nvidia chips to investors and leasing them back.

Amazon is considering a deal to sell $8B of Nvidia Grace Blackwell chips to an SPV, then lease them back. The chips are for AI systems in Amazon's data centers. Investors may finance the SPV, with Amazon potentially offering a 10% stake. The arrangement aims to separate ownership from usage, reducing Amazon's capital expenditure. Nvidia and Amazon have not commented. According to the Financial Times, the deal is not finalized.